All In Biotech

Drug Trial Radar · NCT07241936

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

A Phase Ib/II Clinical Trial on the Safety and Efficacy of Sirolimus (Albumin-bound) Combined With Different ADCs in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

444

Planned (sponsor's estimate)

Start

Nov 13, 2025

Primary completion

Oct 30, 2027

Study completion Oct 30, 2028

Sponsor

Sponsor type
Industry
First posted
Nov 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study adopts a multi-center, open-label, non-randomized trial design. It plans to enroll patients with Advanced solid tumor. Dose-escalation and PK-expansion studies will be carried out to evaluate the safety, tolerability, and preliminary efficacy of sirolimus (albumin-bound) in combination with Different ADCs (DP303c/SYS6043/SYS6002/SYS6010) in this patient population, and to confirm the recommended phase 2 dose (RP2D).

Conditions

  • Advanced Solid Tumors

Interventions

  • sirolimus (albumin-bound)Drug

    intravenous infusion

  • DP303cDrug

    intravenous infusion

  • SYS6043Drug

    intravenous infusion

  • SYS6002Drug

    intravenous infusion

  • SYS6010Drug

    intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The occurrence and frequency of adverse events (AE) and serious adverse events (SAE)Time frame: Up to approximately 36 weeks after the first participant is enrolled
  2. dose - limiting toxicities (DLT)Time frame: Up to approximately 36 weeks after the first participant is enrolled
  3. The recommended phase 2 doseTime frame: Up to approximately 36 weeks after the first participant is enrolled

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.